You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePotassium Iodide
Accession NumberDB06715
TypeSmall Molecule
GroupsApproved
Description

Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperglycemia (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

Structure
Thumb
Synonyms
Kaliumiodid
KI
Potassium iodide
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sskisolution1 g/mLoralUpsher Smith Laboratories, Inc.1973-04-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyrosafetablet65 mgoralRecip Ab2003-11-042008-07-07Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iosattablet65 mg/1oralAnbex Inc.2013-05-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Iosattablet130 mg/1oralAnbex Inc.1982-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyroblock Tab 130mgtablet130 mgoralCarter Horner Corp.1981-12-312003-03-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Thyroshieldsolution65 mg/mLoralFleming & Company, Pharmaceuticals2005-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Thyroshieldsolution65 mg/mLoralArco Pharmaceuticals LLC2014-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Citranatal DHAMission Pharmacal Company
Citranatal RxMission Pharmacal Company
DiodineProduits Marc O (1987) Inc., Division Of Technilab Inc.
Hemenatal ObWh Nutritionals, Llc
Humco Strong Iodine SolutionHumco Holding Group, Inc.
Humco Strong Iodine TinctureHumo Holding Group, Inc.
IodineBorisovskiy Zavod Medicinskikh Preparatov Jsc
Iodine Tct 2.5% BPStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Iodine Tct 5% CFStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Iodine Tincture 21/2%Ingram And Bell Inc.
Lugols Strong IodineCooper Surgical, Inc.
Mathieu Cough SyrupJ L Mathieu Cie Ltee
MetrateMedic Laboratory LtÉe
Prefera Ob Plus DHAAlaven Pharmaceutical LLC
PreferaobMEDA Pharmaceuticals
Preferaob Plus DHAAlaven Pharmaceutical LLC
Prenatal Chelated MineralUsana Health Sciences, Inc.
Prenate StarAvion Pharmaceuticals, Llc
Tincture Of IodineLawton's Drug Stores Ltd.
Tincture Of Iodine 2.5%D.C. Labs Limited
Tincture Of Iodine 5%D.C. Labs Limited
V-natalVirtus Pharmaceuticals
Virt-PNVirtus Pharmaceuticals
Virt-PN PlusVirtus Pharmaceuticals LLC
Vito Bronches SiropDuchesnay Inc
Vp-heme ObVirtus Pharmaceuticals LLC
Vp-heme OneVirtus Pharmaceuticals LLC
SaltsNot Available
CategoriesNot Available
UNII1C4QK22F9J
CAS number7681-11-0
WeightAverage: 166.0028
Monoisotopic: 165.868175281
Chemical FormulaIK
InChI KeyInChIKey=NLKNQRATVPKPDG-UHFFFAOYSA-M
InChI
InChI=1S/HI.K/h1H;/q;+1/p-1
IUPAC Name
potassium iodide
SMILES
[K+].[I-]
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassAlkali metal salts
Sub ClassAlkali metal iodides
Direct ParentAlkali metal iodides
Alternative Parents
Substituents
  • Alkali metal iodide
  • Inorganic salt
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
Pharmacology
IndicationPotassium Iodide is oral antithyroid agent. Potassium Iodide is used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.
PharmacodynamicsIt works in the thyroid gland. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell size is reduced, follicular colloid reaccumulates, and bound iodine levels increase. As a protectant following radiation exposure, KI blocks the uptake of radioactive iodine isotopes by the thyroid gland thereby minimizing the risk of radiation-induced thyroid neoplasms.
Mechanism of actionNot Available
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7647
Blood Brain Barrier+0.9702
Caco-2 permeable+0.6625
P-glycoprotein substrateNon-substrate0.8989
P-glycoprotein inhibitor INon-inhibitor0.984
P-glycoprotein inhibitor IINon-inhibitor0.9854
Renal organic cation transporterNon-inhibitor0.9282
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.7789
CYP450 3A4 substrateNon-substrate0.7857
CYP450 1A2 substrateNon-inhibitor0.7164
CYP450 2C9 inhibitorNon-inhibitor0.8527
CYP450 2D6 inhibitorNon-inhibitor0.9142
CYP450 2C19 inhibitorNon-inhibitor0.8842
CYP450 3A4 inhibitorNon-inhibitor0.9317
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9022
Ames testNon AMES toxic0.6838
CarcinogenicityCarcinogens 0.659
BiodegradationNot ready biodegradable0.5913
Rat acute toxicity2.9202 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9657
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
Liquidoral
Liquidtopical
Solutiontopical
Tincturetopical
Tabletoral130 mg/1
Tabletoral65 mg/1
Syruporal
Tablet, coatedoral
Solutionoral1 g/mL
Tabletoral130 mg
Tabletoral65 mg
Solutionoral65 mg/mL
Tablet, film coatedoral
Capsule, gelatin coatedoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Stanley D. Lazarus, “Production of thermally stabilized polyester with alkylene carbonates and sodium or potassium iodide.” U.S. Patent US4327207, issued October, 1973.

US4327207
General ReferencesNot Available
External Links
ATC CodesR05CA02S01XA04V03AB21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AliskirenPotassium Iodide may increase the hyperkalemic activities of Aliskiren.
ArdeparinArdeparin may increase the hyperkalemic activities of Potassium Iodide.
DicoumarolPotassium Iodide may decrease the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Potassium Iodide.
EplerenoneEplerenone may increase the hyperkalemic activities of Potassium Iodide.
HeparinHeparin may increase the hyperkalemic activities of Potassium Iodide.
LithiumPotassium Iodide may increase the hypothyroid activities of Lithium.
NicorandilNicorandil may increase the hyperkalemic activities of Potassium Iodide.
PerindoprilPotassium Iodide may increase the hyperkalemic activities of Perindopril.
Sodium Iodide I-131The therapeutic efficacy of Sodium Iodide I-131 can be decreased when used in combination with Potassium Iodide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Potassium Iodide.
TriamterenePotassium Iodide may increase the hyperkalemic activities of Triamterene.
ValsartanPotassium Iodide may increase the hyperkalemic activities of Valsartan.
Food InteractionsNot Available

Targets

1. Tyrosine

Kind: Small molecule

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details

References:

  1. Pisarev MA, Aiello LO: Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis. Acta Endocrinol (Copenh). 1976 Jun;82(2):298-305. Pubmed
  2. Foldes J, Gesztesi E, Juhasz J: Mechanism of action of di-iodotyrosine and of iodine. Acta Med Acad Sci Hung. 1974;31(1-2):131-7. Pubmed

Comments
comments powered by Disqus
Drug created on May 16, 2010 17:39 / Updated on September 16, 2013 18:04